公开(公告)号：US09850281B2

公开(公告)日：2017-12-26

申请号：US14403462

申请日：2013-05-30

申请人： Circassia Limited

发明人： Roderick Peter Hafner ,  Paul Laidler ,  Pascal Hickey ,  Mark Larche

IPC分类号： A61K38/00 ,  C07K7/08 ,  A61K39/35 ,  C07K14/37 ,  G01N33/50

CPC分类号： C07K7/08 ,  A61K39/35 ,  C07K14/37 ,  G01N33/505 ,  G01N2800/24

摘要： Polypeptides which may be used for preventing or treating allergy to moulds of the Cladosporium and/or Alternaria genus, have up to 30 amino acids in length and comprise: (I) the amino acid sequence: (a) GGYKAAVRPTMLE (SEQ ID NO: 35; Cla35), (b) AE V YQKLK SLTKK (SEQ ID NO: 31; Cla16), (c) VAITYASRAQGAE (SEQ ID NO: 32; Cla25), (d) GHHFKERGT-GSLVIT (SEQ ID NO: 33; Cla26), or (e) ANYTQTKTVSIRL (SEQ ID NO: 34; Cla29); or (II) a T cell epitope-containing variant sequence which is a said amino acid sequence (I) having up to six amino acid modifications, each of which is independently a deletion, substitution or insertion.

公开(公告)号：US20170319683A1

公开(公告)日：2017-11-09

申请号：US15523544

申请日：2015-11-04

申请人： Memorial Sloan Kettering Cancer Center

发明人： Richard J. O'Reilly ,  Ekaterina Doubrovina ,  Guenther Koehne ,  Aisha N. Hasan ,  Susan E. Prockop

IPC分类号： A61K39/25 ,  G01N33/50 ,  C12Q1/68 ,  A61K39/00 ,  G01N33/574 ,  G06F19/26 ,  C40B30/02

CPC分类号： A61K39/25 ,  A61K35/17 ,  A61K39/0011 ,  A61K2039/5158 ,  A61K2039/572 ,  C12Q1/6881 ,  C12Q2600/136 ,  C12Q2600/172 ,  G01N33/505 ,  G01N33/574 ,  G01N33/57407 ,  G01N2333/03 ,  G01N2333/045 ,  G01N2333/05 ,  G16B35/00 ,  G16B45/00 ,  G16C20/60

摘要： Disclosed herein are methods of selecting an allogeneic T cell line for therapeutic administration to a patient having or suspected of having a pathogen or cancer. Also disclosed are methods of selecting a donor from whom to derive an allogeneic T cell line for therapeutic administration to a patient having or suspected of having a pathogen or cancer.

公开(公告)号：US20170319670A1

公开(公告)日：2017-11-09

申请号：US15412329

申请日：2017-01-23

申请人： Purdue Pharma L.P.

发明人： Donald J. KYLE ,  Daniel A. Soltis ,  Lynda G. Tussey

IPC分类号： A61K39/00 ,  C07K7/06 ,  C07K14/47 ,  G01N33/68 ,  G01N33/50 ,  C12N9/02 ,  C12N9/12

CPC分类号： A61K39/0005 ,  A61K39/00 ,  C07K7/06 ,  C07K14/4747 ,  C07K14/4748 ,  C12N9/0077 ,  C12N9/1241 ,  G01N33/505 ,  G01N33/6878 ,  G01N2333/70539 ,  G01N2500/04 ,  G01N2500/10

摘要： The invention provides for the synthesis of more effective generators of a T-cell immune response by providing peptide derivatives that are MHC class I-restricted antigens. The peptide derivatives of the present invention are prepared or derived from a parent peptide of 8 to 11 amino acid residues in length, wherein the peptide derivative contains a non-natural amino acid substituted in place of a naturally-occurring amino acid residue at one or more primary anchor positions in the parent peptide or at position 6, position 7, or the C-terminus.

公开(公告)号：US20170312336A1

公开(公告)日：2017-11-02

申请号：US15636958

申请日：2017-06-29

申请人： IMMATICS BIOTECHNOLOGIES GMBH

发明人： Jens FRITSCHE ,  Toni WEINSCHENK ,  Steffen WALTER ,  Peter LEWANDROWSKI ,  Harpreet SINGH

IPC分类号： A61K38/17 ,  A61K39/00 ,  G01N33/50 ,  C07K7/06

CPC分类号： A61K38/1709 ,  A61K39/0011 ,  A61K2039/5158 ,  A61K2039/572 ,  A61K2039/585 ,  A61P35/00 ,  C07K7/06 ,  C07K2319/00 ,  G01N33/505

摘要： A method of treating a patient who has gastric cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has gastric cancer. A method of treating a patient who has gastric cancer includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the gastric cancer.

公开(公告)号：US20170285001A1

公开(公告)日：2017-10-05

申请号：US15484024

申请日：2017-04-10

申请人： Alcyomics LTD

发明人： Anne Dickinson

IPC分类号： G01N33/50 ,  G01N33/68 ,  C12Q1/68

CPC分类号： G01N33/505 ,  C12Q1/6809 ,  G01N33/6854

摘要： This present invention provides a method of predicting immunogenicity and hypersensitivity or allergic reactions to chemical compounds, therapeutics, cosmetics and other chemical compositions. The method uses an in vitro assay employing autologous blood derived cells and an autologous cultured skin biopsy and is of particular utility in the identification and prediction of skin sensitizers that cause allergic contact dermatitis.

公开(公告)号：US09775892B2

公开(公告)日：2017-10-03

申请号：US15102681

申请日：2014-12-09

申请人： TARGOVAX ASA

发明人： Jon Amund Eriksen

IPC分类号： A61K38/00 ,  A61K39/00 ,  C07K14/82 ,  G01N33/50 ,  A61K35/17 ,  G01N33/483

CPC分类号： A61K39/0011 ,  A61K35/17 ,  A61K2039/5158 ,  A61K2039/57 ,  A61K2039/70 ,  C07K14/82 ,  C12Q2600/156 ,  G01N33/483 ,  G01N33/505 ,  G01N2333/47

摘要： There is disclosed a peptide mixture suitable for eliciting an immune response. It comprises a first and a second peptide, each corresponding to a fragment of the RAS protein. Each of the first and second peptides comprises a region of at least 8 amino acids which includes position 13 of the RAS protein. Each of said regions of the first and second peptides independently has at least 6 amino acid residues, other than at said position 13, which are identical to the corresponding region of the RAS protein. Each of the first and the second peptides has a point mutation at the amino acid corresponding to said position 13. The point mutation of the first peptide is different from the point mutation of the second peptide.

公开(公告)号：US20170239413A1

公开(公告)日：2017-08-24

申请号：US15493273

申请日：2017-04-21

申请人： Deep Science LLC

发明人： Roderick A. Hyde ,  Lowell L. Wood, Jr.

IPC分类号： A61M1/36 ,  G01N33/50 ,  C12Q3/00 ,  A61B17/435

CPC分类号： A61M1/3689 ,  A61B17/435 ,  B82Y20/00 ,  C12Q3/00 ,  G01N33/505 ,  G01N33/5091 ,  Y10T436/115831

摘要： Devices, systems, or methods are disclosed herein for treatment of disease in a vertebrate subject. The device can include a quasi-planar substrate; and one or more laterally-mobile effector molecule types at least partially embedded within the quasi-planar substrate, wherein the one or more laterally-mobile effector molecule types is configured to interact with one or more cell types. The device can further include one or more sensors configured to detect at least one aspect of an interaction between the at least one of the one or more laterally-mobile effector molecule types and the one or more cell types; and a controller in communication with the one or more sensors, wherein the controller is configured to responsively initiate modification of at least one of the one or more laterally-mobile effector molecule types, the quasi-planar substrate, and the one or more cell types.

公开(公告)号：US09738731B2

公开(公告)日：2017-08-22

申请号：US14772839

申请日：2014-03-10

申请人： TOKYO UNIVERSITY OF SCIENCE FOUNDATION

发明人： Yoichiro Iwakura ,  Ce Tang ,  Naohito Ohno

IPC分类号： A61K31/00 ,  C08B37/00 ,  C12N1/20 ,  C12Q1/02 ,  G01N33/50

CPC分类号： C08B37/0024 ,  C12N1/20 ,  C12Q1/025 ,  G01N33/505 ,  G01N2333/335

摘要： A growth enhancer for Lactobacillus murinus, Lactobacillus salivarius, or a bacterium that belongs to the genus Lactobacillus and that has a homology of 16S rDNA of 90% or higher with Lactobacillus murinus or Lactobacillus salivarius includes a β-glucan having a molecular weight of from 0.2 K to 50 K. A regulatory T-cell number increasing agent, a method of enhancing growth of a lactic acid bacterium, a method of increasing the number of regulatory T-cells, a method of evaluating a regulatory T-cell number increasing effect, and a method of evaluating a growth enhancing effect on a lactic acid bacterium are also provided.

公开(公告)号：US20170219561A1

公开(公告)日：2017-08-03

申请号：US15518864

申请日：2015-10-16

申请人： ASSISTANCE PUBLIQUE HOPITAUX DE PARIS ,  COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES ,  Université Paris Diderot - Paris 7

发明人： François Desgrandchamps ,  Edgardo Delfino Carosella ,  Joël Lemaoult

IPC分类号： G01N33/50 ,  G01N33/574 ,  G01N33/53

CPC分类号： G01N33/505 ,  G01N33/53 ,  G01N33/574 ,  G01N2800/54

摘要： The present invention relates to methods for prognosis and monitoring of a cancer, preferably bladder cancer, by measuring the proportion of CD8+ T Lymphocytes expressing ILT-2 and the plasma level of soluble HLA-G. The invention also relates to anti HLA-G antibodies for use for treating a cancer in which tumor cells express HLA-G, preferably bladder cancer.

公开(公告)号：US09717774B2

公开(公告)日：2017-08-01

申请号：US14615539

申请日：2015-02-06

申请人： immatics biotechnologies GmbH

发明人： Jens Fritsche ,  Toni Weinschenk ,  Steffen Walter ,  Peter Lewandrowski ,  Harpreet Singh

IPC分类号： C07K7/06 ,  A61K38/17 ,  A61K39/00 ,  G01N33/50

CPC分类号： A61K38/1709 ,  A61K39/0011 ,  A61K2039/5158 ,  A61K2039/572 ,  A61K2039/585 ,  A61P35/00 ,  C07K7/06 ,  C07K2319/00 ,  G01N33/505

摘要： The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 95 novel peptide sequences and their variants derived from HLA class I molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.